Sarepta Therapeutics, Inc. NASDAQ:SRPT

Sarepta Therapeutics stock price today

$19.8
-101.7
-83.7%
Financial Health
0
1
2
3
4
5
6
7
8
9

Sarepta Therapeutics stock price monthly change

-20.12%
month

Sarepta Therapeutics stock price quarterly change

-20.12%
quarter

Sarepta Therapeutics stock price yearly change

+25.46%
year

Sarepta Therapeutics key metrics

Market Cap
11.27B
Enterprise value
11.93B
P/E
-16.72
EV/Sales
12.79
EV/EBITDA
-19.37
Price/Sales
12.11
Price/Book
29.36
PEG ratio
0.24
EPS
0.13
Revenue
1.40B
EBITDA
-52.88M
Income
16.89M
Revenue Q/Q
63.10%
Revenue Y/Y
43.82%
Profit margin
-75.4%
Oper. margin
-57.47%
Gross margin
85%
EBIT margin
-57.47%
EBITDA margin
-3.77%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Sarepta Therapeutics stock price history

Sarepta Therapeutics stock forecast

Sarepta Therapeutics financial statements

Average Price Target
Last Year

$185.78

Potential upside: 838.27%

Based on estimate of 8 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Profit margin
Jun 2023 261.23M -23.94M -9.16%
Sep 2023 331.81M -40.93M -12.34%
Dec 2023 396.78M 45.65M 11.51%
Mar 2024 413.46M 36.11M 8.74%
Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Debt to assets
Jun 2023 3125890000 2.38B 76.28%
Sep 2023 3109707000 2.34B 75.42%
Dec 2023 3264576000 2.40B 73.68%
Mar 2024 3224385000 2.26B 70.19%
Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Cash Flow
Jun 2023 -122.23M 96.63M 5.86M
Sep 2023 -114.70M -210.57M 15.40M
Dec 2023 -54.65M -64.35M 1.94M
Mar 2024 -242.07M 218.79M 22.14M

Sarepta Therapeutics alternative data

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Employee count
Aug 2023 1,162
Sep 2023 1,162
Oct 2023 1,162
Nov 2023 1,162
Dec 2023 1,162
Jan 2024 1,162
Feb 2024 1,162
Mar 2024 1,314
Apr 2024 1,314
May 2024 1,314
Jun 2024 1,314
Jul 2024 1,314

Sarepta Therapeutics other data

87.81% -12.19%
of SRPT is owned by hedge funds
71.35M +347.23K
shares is hold by hedge funds

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Insider trades (number of shares)
Period Buy Sel
Mar 2024 0 24096
May 2024 0 3635
Jun 2024 0 50714
Aug 2024 37038 5985
Dec 2024 0 12136
Transaction Date Insider Security Shares Price per share Total value Source
Option
WIGZELL HANS LENNART RUDOLF director
Common Stock 10,500 $13.71 $143,955
Sale
WIGZELL HANS LENNART RUDOLF director
Common Stock 10,500 $124.84 $1,310,820
Option
WIGZELL HANS LENNART RUDOLF director
Stock Options (right to buy) 10,500 $13.71 $143,955
Sale
BOOR KATHRYN JEAN director
Common Stock 1,636 $125.55 $205,400
Sale
ESTEPAN IAN MICHAEL officer: Chief Fi.. Common Stock 5,985 $137.36 $822,100
Purchase
CHAMBERS MICHAEL ANDREW director
Common Stock 5,648 $134.66 $760,560
Purchase
CHAMBERS MICHAEL ANDREW director
Common Stock 18,284 $134.06 $2,451,153
Purchase
CHAMBERS MICHAEL ANDREW director
Common Stock 13,106 $133.07 $1,744,015
Option
BEHRENS M KATHLEEN director
Common Stock 15,000 $13.9 $208,500
Option
BEHRENS M KATHLEEN director
Stock Option (right to buy) 15,000 $13.9 $208,500
Patent
Grant
Filling date: 30 Apr 2021 Issue date: 26 Jul 2022
Grant
Filling date: 16 Nov 2020 Issue date: 12 Jul 2022
Grant
Filling date: 14 Dec 2017 Issue date: 12 Jul 2022
Grant
Filling date: 24 Jul 2020 Issue date: 24 May 2022
Application
Filling date: 15 Apr 2021 Issue date: 24 Mar 2022
Application
Filling date: 21 Oct 2021 Issue date: 3 Feb 2022
Application
Filling date: 17 Sep 2021 Issue date: 3 Feb 2022
Grant
Filling date: 5 Sep 2014 Issue date: 1 Feb 2022
Application
Filling date: 11 Jun 2021 Issue date: 20 Jan 2022
Grant
Filling date: 20 May 2019 Issue date: 28 Dec 2021
Friday, 20 December 2024
reuters.com
Thursday, 19 December 2024
zacks.com
zacks.com
Wednesday, 18 December 2024
businesswire.com
Tuesday, 17 December 2024
zacks.com
Friday, 13 December 2024
proactiveinvestors.com
zacks.com
Monday, 9 December 2024
zacks.com
Friday, 29 November 2024
businesswire.com
zacks.com
Wednesday, 27 November 2024
zacks.com
zacks.com
Tuesday, 26 November 2024
businesswire.com
Friday, 8 November 2024
seekingalpha.com
Thursday, 7 November 2024
zacks.com
seekingalpha.com
Wednesday, 6 November 2024
zacks.com
Wednesday, 23 October 2024
businesswire.com
Thursday, 17 October 2024
fool.com
Thursday, 3 October 2024
fool.com
Monday, 30 September 2024
businesswire.com
Thursday, 26 September 2024
businesswire.com
Wednesday, 18 September 2024
seekingalpha.com
247wallst.com
Friday, 13 September 2024
fool.com
Friday, 6 September 2024
zacks.com
Friday, 30 August 2024
businesswire.com
Monday, 19 August 2024
schaeffersresearch.com
Wednesday, 14 August 2024
forbes.com
Monday, 12 August 2024
fool.com
  • What's the price of Sarepta Therapeutics stock today?

    One share of Sarepta Therapeutics stock can currently be purchased for approximately $19.8.

  • When is Sarepta Therapeutics's next earnings date?

    Unfortunately, Sarepta Therapeutics's (SRPT) next earnings date is currently unknown.

  • Does Sarepta Therapeutics pay dividends?

    No, Sarepta Therapeutics does not pay dividends.

  • How much money does Sarepta Therapeutics make?

    Sarepta Therapeutics has a market capitalization of 11.27B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.26% to 1.24B US dollars.

  • What is Sarepta Therapeutics's stock symbol?

    Sarepta Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SRPT".

  • What is Sarepta Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Sarepta Therapeutics?

    Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Sarepta Therapeutics's key executives?

    Sarepta Therapeutics's management team includes the following people:

    • Mr. Douglas S. Ingram Pres, Chief Executive Officer & Director(age: 62, pay: $1,290,000)
    • Dr. Gilmore O'Neill M.D. Executive Officer(age: 60, pay: $891,940)
    • Dr. Louise Rodino-Klapac Ph.D. Chief Scientific Officer and Head of R&D(age: 47, pay: $739,050)
    • Mr. Ian Michael Estepan Executive Vice President & Chief Financial Officer(age: 49, pay: $684,120)
    • Mr. William F. Ciambrone Executive Vice President of Technical Operations(age: 61, pay: $679,940)
    • Mr. Joseph Bratica Controller & Vice President(age: 61, pay: $438,510)
  • How many employees does Sarepta Therapeutics have?

    As Jul 2024, Sarepta Therapeutics employs 1,314 workers.

  • When Sarepta Therapeutics went public?

    Sarepta Therapeutics, Inc. is publicly traded company for more then 28 years since IPO on 4 Jun 1997.

  • What is Sarepta Therapeutics's official website?

    The official website for Sarepta Therapeutics is sarepta.com.

  • Where are Sarepta Therapeutics's headquarters?

    Sarepta Therapeutics is headquartered at 215 First Street, Cambridge, MA.

  • How can i contact Sarepta Therapeutics?

    Sarepta Therapeutics's mailing address is 215 First Street, Cambridge, MA and company can be reached via phone at +61 72744000.

  • What is Sarepta Therapeutics stock forecast & price target?

    Based on 8 Wall Street analysts` predicted price targets for Sarepta Therapeutics in the last 12 months, the avarage price target is $185.78. The average price target represents a 838.27% change from the last price of $19.8.

Sarepta Therapeutics company profile:

Sarepta Therapeutics, Inc.

sarepta.com
Exchange:

NASDAQ

Full time employees:

1,314

Industry:

Biotechnology

Sector:

Healthcare

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

215 First Street
Cambridge, MA 02142

CIK: 0000873303
ISIN: US8036071004
CUSIP: 803607100